Genocea Biosciences (NASDAQ:GNCA) Coverage Initiated by Analysts at initiated coverage on shares of Genocea Biosciences (NASDAQ:GNCAGet Rating) in a research note published on Saturday. The firm issued a sell rating on the biotechnology company’s stock.

Genocea Biosciences Stock Performance

Shares of GNCA opened at $0.01 on Friday. The company has a 50-day simple moving average of $0.01 and a 200-day simple moving average of $0.35. The company has a quick ratio of 1.35, a current ratio of 1.35 and a debt-to-equity ratio of 0.24. The company has a market capitalization of $657,776.00, a PE ratio of -0.02 and a beta of 1.96. Genocea Biosciences has a 52-week low of $0.01 and a 52-week high of $2.16.

Hedge Funds Weigh In On Genocea Biosciences

An institutional investor recently bought a new position in Genocea Biosciences stock. Acadian Asset Management LLC purchased a new stake in Genocea Biosciences, Inc. (NASDAQ:GNCAGet Rating) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 21,741 shares of the biotechnology company’s stock, valued at approximately $25,000. 9.31% of the stock is currently owned by institutional investors and hedge funds.

Genocea Biosciences Company Profile

(Get Rating)

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.

Read More

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with's FREE daily email newsletter.